Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs

Conclusion: Among subjects with rheumatoid arthritis, TNF-α blocking agents may be associated with a reduced risk of cardiovascular events compared with an nbDMARD. Randomized controlled clinical trials should be considered to test this hypothesis.

Source: The American Journal of Medicine - July 26, 2013 Category: Journals (General) Authors: Daniel H. Solomon, Jeffrey R. Curtis, Kenneth G. Saag, Joyce Lii, Lang Chen, Leslie R. Harrold, Lisa J. Herrinton, David J. Graham, Mary K. Kowal, Bindee Kuriya, Liyan Liu, Marie R. Griffin, James D. Lewis, Jeremy A. Rassen Tags: Clinical research studies Source Type: research